Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody

YUAN Xiaojun

PDF(3645 KB)
主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
PDF(3645 KB)
World Clinical Drug ›› 2022, Vol. 43 ›› Issue (08) : 967-974. DOI: 10.13683/j.wph.2022.08.002
Topic

Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 43(08): 967-974 https://doi.org/10.13683/j.wph.2022.08.002

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(3645 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉